Cue Biopharma
NASDAQ: CUEBoston, US · Founded 2014 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
DB
Daniel BakerExecutive Officer
CS
Colin SandercockExecutive Officer
DB
Dominic BorieExecutive Officer
SR
Sumita RayExecutive Officer
DC
Daniel CamardoDirector
VM
Viola MeehanDirector
MM
Michael MeluzioExecutive Officer
RC
Rodolfo ChaparroVice President, Head of Immunology
RS
Ronald Seidel IIIExecutive Vice President, Head of Research and Development
CM
Christopher MarlettDirector
GS
Gary SchumanChief Financial Officer
CG
Cameron GrayChief Executive Officer and President
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$50MraisedJul 2026 · 4 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shao-Lee LinExecutive Officer, Director
- Dominic BorieExecutive Officer
- Sumita RayExecutive Officer
- Daniel CamardoDirector
- Pamela GarzoneDirector
- Viola MeehanDirector
- Pasha SarrafDirector
- Michael MeluzioExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedMay 2026 · 118 investors · BiotechnologyRule 506(b)
▶$30MraisedMay 2026 · 118 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick VerheyenDirector
- Daniel BakerExecutive Officer
- Peter KienerDirector
- Frank MorichDirector
- Pamela D. GarzoneDirector
- Colin SandercockExecutive Officer
- Jill M. BroadfootDirector
- Shao-Lee LinExecutive Officer, Director
- Pasha SarrafDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Newbridge Securities Corporation
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedNov 2022 · 64 investors · BiotechnologyRule 506(b)
▶$30MraisedNov 2022 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tamar HowsonDirector
- Daniel R. PasseriExecutive Officer, Director
- Aaron FletcherDirector
- Peter A. KienerDirector
- Kerri-Ann MillarExecutive Officer
- Anish SuriExecutive Officer
- Frank MorichDirector
- Frederick DriscollDirector
- Patricia NasshornExecutive Officer
- Colin G. SandercockExecutive Officer
- Ken PientaExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Public Ventures, LLC, Piper Sandler & Co.
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.4MraisedDec 2016 · 133 investors · BiotechnologyRule 506(b)
▶$16.4MraisedDec 2016 · 133 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD SEIDEL IIIExecutive Officer
- ANTHONY DIGIANDOMENICODirector
- CAMERON GRAYDirector
- GARY SCHUMANExecutive Officer
- STEVEN MCKNIGHTDirector
- AMY WANGDirector
- RODOLFO CHAPARROExecutive Officer
- DANIEL PASSERIExecutive Officer, Director
- CHRISTOPHER MARLETTDirector
- PETER KIENERDirector
- BARRY SIMONDirector
- Offering amount
- $16.4M
- Amount sold
- $16.4M
- Sales commissions
- $1.3M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10MraisedJun 2015 · 121 investors · BiotechnologyRule 506(b)
▶$10MraisedJun 2015 · 121 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary SchumanExecutive Officer, Director
- Christopher MarlettDirector
- Steven AlmoExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Anthony DiGiandomenicoDirector
- Cameron GrayExecutive Officer, Director
- Amy WangExecutive Officer, Director
- Rodolfo ChaparroExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MofferedJun 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1MofferedJun 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodolfo ChaparroExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Christopher MarlettDirector
- Gary SchumanExecutive Officer, Director
- Cameron GrayExecutive Officer, Director
- Anthony DiGiandomenicoDirector
- Amy WangExecutive Officer, Director
- Steven AlmoExecutive Officer
- Offering amount
- $1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - BioSpacebiospace.com · 2026
- Cue Biopharma Appoints Veteran James Ahlers as CFO - TipRanks.comtipranks.com · 2026
- Cue Biopharma raises $49,999,927 in private offering | CUE SEC Filing - Form Dstocktitan.net · 2026
- Intellectiaintellectia.ai · 2026
- Cue Biopharma raises $50M in private stock deal | CUE 8-K Filingstocktitan.net · 2026
- Cue Biopharma (CUE) Secures $50M in Private Placement Financinggurufocus.com · 2026
- Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugsstocktitan.net · 2026